YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell line
Yasuto Akiyama(Shizuoka Cancer Center), Ken Yamaguchi(Shizuoka Cancer Center)
Cited by 36
Related Papers
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line
|Cancer Genomics & Proteomics|2017|41
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell line
|International Journal of Oncology|2014|40